Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AHCL.NS
Strong BuyPremium GrowerAnlon Healthcare Limited · Healthcare · India · $88M · Avg Vol: $724K/d
90
StockRankGet insider-trade alerts
Q
60
V
44
M
85
P/E (TTM)
23.6x
ROE
12.4%
D/E
0.2x
Dividend %
—
COMPANY DESCRIPTION
Anlon Healthcare Limited manufactures and sells active pharmaceutical ingredients in India and internationally. The company also offers bulk drugs; advanced pharmaceutical intermediates; nutraceutical API products; and drug intermediates.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 1.1B | 665.8M | 1.2B | 1.7B | 15.1% | 2.3B |
| EPS (INR) | 0.11 | 0.18 | 0.39 | 0.60 | 76.2% | 0.69 |
| Shares | 531.5M | 531.5M | 531.5M | 531.5M | 0.0% | 531.5M |
| Debt | 703.2M | 812.5M | 665.5M | 436.5M | -14.7% | 436.5M |
| Equity | 73.7M | 210.3M | 804.2M | 2.3B | 214.9% | — |
| Op CF | -28.5M | -32.3M | -225.5M | -794.4M | — | -794.4M |
| Inv CF | -3.3M | -33.7M | 27.9M | -363.4M | — | — |
| Fin CF | 22.7M | 82.5M | 189.4M | 1.2B | — | — |
Loading 1Y...
PRICE (1Y)+12.1%
SMA 50SMA 200
Close
$0.1712
RSI (14)
73.3
52W High
$0.1816
From 52W High
0.9%
SCORE BREAKDOWN
Quality
60
ROIC
557.4%100.0
ROE
12.4%76.8
GP/Assets
21.2%46.8
Op. Margin
16.6%78.0
FCF/Assets
-31.0%13.0
Piotroski
549.3
Int. Cover
50.0x89.2
D/E Ratio
0.17x53.2
Current Ratio
2.87x53.5
Value
44
P/E (TTM)
23.6x52.0
EV/EBITDA
12.7x57.4
P/FCF
—N/A
P/B
3.2x43.9
P/S
3.8x49.9
Div Yield
—N/A
Momentum
85
52W High %
94%92.4
RS 6M
32%86.1
SMA 50/200
1.08x73.2
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
88%82.1
FUNDAMENTALS
Market Cap
$88M
P/E (Forward)
—
Gross Margin
35.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AHCL.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AHCL.NS | Anlon Healthcare Limited(you) | $88M | 90 | Strong Buy |
| ANUHPHR.NS | Anuh Pharma Limited | $101M | 94 | Strong Buy |
| AMANTA.NS | Amanta Healthcare Limited | $83M | 81 | Strong Buy |
| VALIANTLAB.NS | Valiant Laboratories Limited | $65M | 83 | Strong Buy |
| ALBERTDAVD.NS | Albert David Limited | $51M | 93 | Strong Buy |
| JAGSNPHARM.NS | Jagsonpal Pharmaceuticals Limited | $165M | 94 | Strong Buy |
| LINCOLN.NS | Lincoln Pharmaceuticals Limited | $135M | 99 | Strong Buy |
| WANBURY.NS | Wanbury Limited | $91M | 69 | Buy |
| SYNCOMF.NS | Syncom Formulations (India) Limited | $208M | 96 | Strong Buy |
| WINDLAS.NS | Windlas Biotech Limited | $248M | 84 | Strong Buy |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%